Episode Details
Back to Episodes
Revvity Q1: Beats Expectations, Trims Guidance
Description
Revvitys Q1 earnings missed expectations but still impressed the market, with revenue at $686.9M, up 9.3% YoY, and adjusted EPS at $1.06, beating forecasts. Adjusted EBITDA soared to $270.1M, exceeding predictions. Organic revenue grew 3% YoY, driven by life sciences and diagnostics. The stock surged on beats, but full-year guidance was trimmed. Operating margins jumped to 11.7% from 3.2% last year. Analysts focused on the China immunodiagnostics divestiture, with management prioritizing high-return buys and share repurchases over big deals. Keep watch on the China deal, AI software, new instruments, and demand recovery in key sectors.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/cf4d99682bd43f17